Characterizing the impact of renal impairment on the clinical pharmacology of biologics.
about
Pharmacokinetic considerations in the treatment of multiple sclerosis with interferon-β.A hybrid protein-polymer nanoworm potentiates apoptosis better than a monoclonal antibodyA survey of renal impairment pharmacokinetic studies for new oncology drug approvals in the USA from 2010 to early 2015: a focus on development strategies and future directionsPopulation pharmacokinetic modeling of LY2189102 after multiple intravenous and subcutaneous administrationsNovel exenatide analogs with peptidic albumin binding domains: potent anti-diabetic agents with extended duration of actionThe pharmacokinetics of peginterferon lambda-1a following single dose administration to subjects with impaired renal functionChemical Conjugation of Evans Blue Derivative: A Strategy to Develop Long-Acting Therapeutics through Albumin Binding.Pharmacokinetics of the Long-Acting Basal Insulin LY2605541 in Subjects With Varying Degrees of Renal Function.Pharmacokinetics and pharmacokinetic-pharmacodynamic correlations of therapeutic peptides.Clinical pharmacology of albiglutide, a GLP-1 receptor agonist.Clinical pharmacology of bispecific antibody constructs.Tools for predicting the PK/PD of therapeutic proteins.Potential Sources of Inter-Subject Variability in Monoclonal Antibody Pharmacokinetics.Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.Drug Development of Therapeutic Monoclonal Antibodies.Safety issues and management of toxicities associated with new treatments for multiple myeloma.Pharmacokinetic and pharmacodynamic properties of canakinumab in patients with gouty arthritis.Efficacy and safety of anakinra in tumor necrosis factor receptor-associated periodic syndrome (TRAPS) complicated by severe renal failure: a report after long-term follow-up and review of the literature.Idarucizumab for the treatment of hemorrhage and dabigatran reversal in patients requiring urgent surgery or procedures.[Dosage and toxicity of antirheumatic drugs in renal insufficiency].Population pharmacokinetics of exendin-(9-39) and clinical dose selection in patients with congenital hyperinsulinism.The recommended dose of idarucizumab may not always be sufficient for sustained reversal of dabigatran.ADME for Therapeutic Biologics: Antibody-Derived Proteins and Proteins with Novel Scaffolds
P2860
Q30379738-010AEAEE-E4EA-476B-AB04-0731FFCFB221Q30420026-61DB1597-CDFC-4210-82C7-E635E66FE1CDQ30491777-1ED61C68-19D6-4CF9-BA55-1E9FA5B12DA1Q34099832-1C9FF5EB-4430-4C28-91F2-D96CE7B915ADQ35087618-7C01073E-B43E-4585-A504-6FCB6C5AC48DQ36072498-6B06F15E-E66B-489D-810E-BB524BEF6F64Q36510864-EE1E1BFE-F2C7-466E-9AEB-8AE053BBB359Q37352359-9798FF93-FF2A-424A-B3A7-6781C5430526Q38110433-FBA076EE-7159-4AC5-B910-AFC67213A068Q38267138-5FBBC0D1-70C7-4095-9E1B-197802D3484BQ38364459-8D853D99-16C1-4F11-8A5B-6461DC569227Q38455786-862E8371-5CA3-4268-994B-818D5C0F2D7AQ38714339-A9C94141-64FC-4F15-A39C-647DB0A6B4A4Q38792725-7B401C57-9EF5-4FAB-8599-93BED79F7331Q38876360-9CA407AF-A504-4C81-9BF4-CB1877D36666Q39100317-5904AB7B-20A6-414D-AA9D-B65B7DA453E3Q39219045-84AB713F-93A2-4019-A9E0-646B1659BF30Q39325689-3EAB8B11-F179-419B-9301-8657601DB1FBQ39448172-DDC26C69-5BDF-4D2E-9D67-7897FF74CE25Q41241653-350D48B3-9AA6-4626-AD2D-FC534D9420CFQ47872785-42E10E22-25E2-488C-8844-89B021F41655Q48252493-97016394-1BD9-4BF3-868C-299DD0DB60B0Q58869554-3163AC05-21AC-44CF-AB98-E2F8D9F7871E
P2860
Characterizing the impact of renal impairment on the clinical pharmacology of biologics.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Characterizing the impact of renal impairment on the clinical pharmacology of biologics.
@en
Characterizing the impact of renal impairment on the clinical pharmacology of biologics.
@nl
type
label
Characterizing the impact of renal impairment on the clinical pharmacology of biologics.
@en
Characterizing the impact of renal impairment on the clinical pharmacology of biologics.
@nl
prefLabel
Characterizing the impact of renal impairment on the clinical pharmacology of biologics.
@en
Characterizing the impact of renal impairment on the clinical pharmacology of biologics.
@nl
P2860
P356
P1476
Characterizing the impact of renal impairment on the clinical pharmacology of biologics.
@en
P2093
Bernd Meibohm
Honghui Zhou
P2860
P304
P356
10.1177/0091270011413894
P433
P577
2012-01-01T00:00:00Z